Back to results

CompletedPhase 2

Fulvestrant (FASLODEX™) as a Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer

NCT00093002

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Research Site

Little Rock, Arkansas, United States

+30 additional locations

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2004-06
Enrollment: 179 participants
Sponsor: AstraZeneca
Purpose: treatment

Locations (31)

Research SiteLittle Rock, Arkansas, United States
Research SiteBoston, Massachusetts, United States
Research SiteWinchester, Massachusetts, United States
Research SiteAlbuquerque, New Mexico, United States
Research SiteHershey, Pennsylvania, United States
Research SiteNashville, Tennessee, United States
Research SiteLaredo, Texas, United States
Research SiteInnsbruck, Austria
Research SiteSalzburg, Austria
Research SiteVienna, Austria
Research SiteBarretos, Brazil
Research SiteFlorianópolis, Brazil
Research SiteGoiamia, Brazil
Research SitePorto Alegre, Brazil
Research SiteRio de Janeiro, Brazil
Research SiteSanto André, Brazil
Research SiteSão Paulo, Brazil
Research SiteBerlin, Germany
Research SiteHanover, Germany
Research SiteMagdeburg, Germany
Research SiteMünchen, Germany
Research SiteRostock, Germany
Research SiteBangalore, India
Research SiteHyderabaad, India
Research SiteNew Delhi, India
Research SitePune, India
Research SiteTrivandrum, India
Research SiteBirmingham, United Kingdom
Research SiteBournemouth, United Kingdom
Research SiteDundee, United Kingdom
Research SiteEdinburgh, United Kingdom

Fulvestrant (FASLODEX™) as a Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer — TrialFind